Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2004

Open Access 01-12-2004 | Research article

Effects of chemokines on proliferation and apoptosis of human mesangial cells

Authors: Markus Wörnle, Holger Schmid, Monika Merkle, Bernhard Banas

Published in: BMC Nephrology | Issue 1/2004

Login to get access

Abstract

Background

Proliferation and apoptosis of mesangial cells (MC) are important mechanisms during nephrogenesis, for the maintenance of glomerular homeostasis as well as in renal disease and glomerular regeneration. Expression of chemokines and chemokine receptors by intrinsic renal cells, e.g. SLC/CCL21 on podocytes and CCR7 on MC is suggested to play a pivotal role during these processes. Therefore the effect of selected chemokines on MC proliferation and apoptosis was studied.

Methods

Proliferation assays, cell death assays including cell cycle analysis, hoechst stain and measurement of caspase-3 activity were performed.

Results

A dose-dependent, mesangioproliferative effect of the chemokine SLC/CCL21, which is constitutively expressed on human podocytes was seen via activation of the chemokine receptor CCR7, which is constitutively expressed on MC. In addition, in cultured MC SLC/CCL21 had a protective effect on cell survival in Fas-mediated apoptosis. The CXCR3 ligands IP-10/CXCL10 and Mig/CXCL9 revealed a proproliferative effect but did not influence apoptosis of MC. Both the CCR1 ligand RANTES/CCL5 and the amino-terminally modified RANTES analogue Met-RANTES which blocks CCR1 signalling had no effect on proliferation and apoptosis.

Conclusions

The different effects of chemokines and their respective receptors on proliferation and apoptosis of MC suggest highly regulated, novel biological functions of chemokine/chemokine receptor pairs in processes involved in renal inflammation, regeneration and glomerular homeostasis.
Appendix
Available only for authorised users
Literature
1.
Luster AD: Chemokines: Chemotactic cytokines that mediate inflammation. N Engl J Med. 1998, 338: 436-445. 10.1056/NEJM199802123380706.CrossRefPubMed
2.
Muller A, Homey B, Soto N, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56. 10.1038/35065016.CrossRefPubMed
3.
Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura K, Matsushima N, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998, 393: 591-594. 10.1038/31261.CrossRefPubMed
4.
Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littmann DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998, 393: 595-599. 10.1038/31269.CrossRefPubMed
5.
Mackay CR, Chemokines : What chemokine is that?. Curr Biol. 1997, 7: R384-386. 10.1016/S0960-9822(06)00181-3.CrossRefPubMed
6.
7.
Murphy PM, Baggiolini M, Charo IF, Herbert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000, 52: 145-176.PubMed
8.
Segerer S, Nelson PJ, Schlöndorff D: Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol. 2000, 11: 152-176.PubMed
9.
Banas B, Luckow B, Möller M, Klier C, Nelson PJ, Schadde E, Brigl M, Halevy D, Holthöfer H, Reinhart B, Schlöndorff D: Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol. 1999, 10: 2314-2322.PubMed
10.
Gomez-Chiarri M, Hamilton TA, Egido J, Emancipator SN: Expression of IP-10, a lipopolysaccharide- and interferon-gamma-inducible protein, in murine mesangial cells in culture. Am J Pathol. 1993, 142: 433-439.PubMedPubMedCentral
11.
Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, Cosmi L, Maggi E, Salvadori M, Pupilli C, Serio M: Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol. 1999, 10: 2518-2526.PubMed
12.
Banas B, Wörnle M, Berger T, Nelson PJ, Cohen CD, Kretzler M, Pfirstinger J, Mack M, Lipp M, Gröne HJ, Schlöndorff D: Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis and tissue homeostasis. J Immunol. 2002, 168: 4301-4307.CrossRefPubMed
13.
14.
Schlöndorff D, Nelson PJ, Luckow B, Banas B: Chemokines and renal disease. Kidney Int. 1997, 51: 610-621.CrossRefPubMed
15.
Heeg K, Reimann J, Kabelitz D, Hardt C, Wagner H: A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J Immunol Methods. 1985, 77: 237-246. 10.1016/0022-1759(85)90036-5.CrossRefPubMed
16.
Gonzales-Cuadrado S, Lopez-Armada MJ, Gomez-Guerrero C, Subira D, Garcia-Sahuquillo A, Ortiz-Gonzales A, Neilson EG, Egido J, Ortiz A: Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. Kidney Int. 1996, 49: 1064-1070.CrossRef
17.
Berger T, Brigl M, Hermann JM, Vielhauer V, Luckow B, Schlöndorff D, Kretzler M: The apoptosis mediator mDAP-3 is a novel member of a conserved family of mitochondrial proteins. J Cell Sci. 2000, 113: 3603-3612.PubMed
18.
Fernandes-Alnemri T, Litwack G, Alnemeri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994, 269: 30761-30764.PubMed
19.
Roos A, Sato T, Maier H, van Kooten C, Daha MR: Induction of renal cell apoptosis by antibodies and complement. Exp Nephrol. 2001, 9: 65-70. 10.1159/000052596.CrossRefPubMed
20.
Krammer PH: CD95's deadly mission in the immune system. Nature. 2000, 407: 789-795. 10.1038/35037728.CrossRefPubMed
21.
Ortiz A, Lorz C, Egido J: New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol. 1999, 12: 150-158.PubMed
22.
Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomen with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26: 239-257.CrossRefPubMedPubMedCentral
23.
Hale AJ, Smith CA, Sutherland LC, Stoneman VE, Longthorne VL, Culhane AC, Wiliams GT: Apoptosis: molecular regulation of cell death. Eur J Biochem. 1996, 236: 1-26.CrossRefPubMed
24.
Baker AJ, Mooney A, Hughes J, Lombardi D, Jonson RJ, Savill J: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest. 1994, 94: 2105-2116.CrossRefPubMedPubMedCentral
25.
Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N: Apoptosis in the repair of experimental proliverative glomerulonephritis. Kidney Int. 1995, 47: 114-121.CrossRefPubMed
26.
Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N: Apoptosis in progressive crescent glomerulonephritis. Lab Invest. 1996, 74: 941-951.PubMed
27.
Ortiz A, Lorz C, Justo P, Catalan MP, Egido J: Contribution of apoptotic cell death to renal injury. J Cell Mol Med. 2001, 5: 18-32.CrossRefPubMed
28.
Wang W, Tzanidis A, Divjak M, Thomson NM, Stein-Oakley AN: Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis. J Am Soc Nephrol. 2001, 12: 1422-1433.PubMed
29.
Kitching AR, Katerelos M, Mudge SJ, Tipping PG, Power DA, Holdsworth SR: Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol. 2002, 128: 36-43. 10.1046/j.1365-2249.2002.01793.x.CrossRefPubMedPubMedCentral
30.
Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG: Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int. 1995, 48: 45-51.CrossRefPubMed
31.
Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF, Johnson RJ: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest. 1993, 92: 2952-2962.CrossRefPubMedPubMedCentral
32.
Sano H, Ueda Y, Takakura N, Takemura G, Doi T, Kataoka H, Murayama T, Xu Y, Sudo T, Nishikawa S, Nishikawa S, Fujiwara H, Kita T, Yokode M: Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am J Pathol. 2002, 161: 135-143.CrossRefPubMedPubMedCentral
33.
Campbell JJ, Bowman EP, Murphy K, Youngman KR, Siani MA, Thompson DA, Wu L, Zlotnik A, Butcher EC: 6-C-kine (SLC), a lymphocyte adhesion triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7. J Cell Biol. 1998, 141: 1053-1059. 10.1083/jcb.141.4.1053.CrossRefPubMedPubMedCentral
34.
Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998, 188: 373-386. 10.1084/jem.188.2.373.CrossRefPubMedPubMedCentral
35.
Cyster JG: Leukocyte migration: scent of the T zone. Curr Biol. 2000, 10: R30-33. 10.1016/S0960-9822(99)00253-5.CrossRefPubMed
36.
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999, 401: 708-712. 10.1038/44385.CrossRefPubMed
37.
Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol. 2000, 165: 397-403.CrossRefPubMed
38.
Anders HJ, Vielhauer V, Kretzler M, Cohen CD, Segerer S, Luckow B, Weller L, Gröne HJ, Schlöndorff D: Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. J Am Soc Nephrol. 2001, 12: 919-931.PubMed
39.
Topham PS, Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DJ, Hancock WW: Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest. 1999, 104: 1549-1557.CrossRefPubMedPubMedCentral
40.
Anders HJ, Frink M, Linde Y, Banas B, Wörnle M, Cohen CD, Vielhauer V, Nelson PJ, Grone HJ, Schlöndorff D: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol. 2003, 170: 5658-5666.CrossRefPubMed
Metadata
Title
Effects of chemokines on proliferation and apoptosis of human mesangial cells
Authors
Markus Wörnle
Holger Schmid
Monika Merkle
Bernhard Banas
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2004
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-5-8

Other articles of this Issue 1/2004

BMC Nephrology 1/2004 Go to the issue

Case report

Severe symptomatic hyponatremia during citalopram therapy - a case report

Case report

Successful recovery of infective endocarditis-induced rapidly progressive glomerulonephritis by steroid therapy combined with antibiotics: a case report

Research article

Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme

Research article

Atherosclerotic renal artery stenosis: one year outcome of total and separate kidney function following stenting

Research article

Comparison of glucose tolerance in renal transplant recipients and hemodialysis patients

Research article

Race/ethnicity and disease severity in IgA nephropathy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits